Social distancing may be necessary for two years or more. Here's where remote care comes into play.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

An overview of mix shift modeling, including varying recovery scenarios, margin impact, and possible future legislation.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

Part 3: One Size Does Not Fit All

A closer look at unemployment, member migration, and financial impact amidst an ever-changing pandemic.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

Part 2: Healthcare’s ‘Corona Effect’

Ten expectations regarding voluntary offerings, telemedicine, direct contracting, and more as COVID-19 unfolds.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Here's how we did on last year's predictions and what emerging trends to expect next.

Partner, Health and Life Sciences, Oliver Wyman
Partner, Head of Health & Life Sciences, Asia Pacific, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman
Manager, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.

Partner, Health and Life Sciences, Oliver Wyman
Former Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

How New Price Transparency Rules May Impact Payers and Providers

Immediate considerations for the industry.

Partner, Health and Life Sciences, Oliver Wyman
Global Head, Health Services, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Practice Leader, Oliver Wyman Actuarial Consulting

Oliver Wyman's research findings on diversity in healthcare leadership (some of which surprised us).

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Director, Strategy & Corporate Development, Landmark Health
Principal, Oliver Wyman
Consultant

An analysis of annual premiums by federal poverty level.

Practice Leader, Oliver Wyman Actuarial Consulting

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health and Life Sciences, Oliver Wyman
Senior Knowledge Expert, Oliver Wyman

Insights in your inbox

Subscribe
Load More